Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opening Session Panel Discussion

Advertisement

Advertisement




Aug
21
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo